LONDON, Aug. 21, 2013 /PRNewswire/ -- Lightlake
Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a
biopharmaceutical company developing addiction treatments based on
its expertise in opioid antagonists, announced today the Company is
moving forward in expanding access to medication for the treatment
of opioid overdose with the National Institute on Drug Abuse
("NIDA"), part of the National Institutes of Health ("NIH"). This
fall, NIDA will sponsor a two-week clinical study designed to
evaluate the pharmacokinetic properties of Lightlake's intranasal
naloxone application in 14 healthy volunteer subjects.
Naloxone is an injectable medicine that can rapidly reverse the
overdose of prescription and illicit opioids. Lightlake is working
on a new intranasal delivery system for the delivery of naloxone
that could widely expand its availability and use in preventing
opioid overdose deaths, a public health problem of epidemic
proportion in the U.S. According to the Centers for Disease Control
and Prevention, 16,651 people died from prescription opioid
overdose in the U.S. in 2010, a significant increase from the 4,030
overdose deaths in 1999.
Assuming favorable outcomes from this study, NIDA plans to file
an IND for a larger study. The expected goal of this partnership is
to have an FDA approved intranasal naloxone solution for the
reversal of opioid overdoses that can be brought to market within
12 to 18 months.
"Naloxone is a lifesaving drug used in an emergency to treat
patients who have overdosed on opioids such as heroin or oxycodone.
It's proven to be very safe and has been used for decades," said
Dr. Roger Crystal, CEO of Lightlake
Therapeutics. "The problem is that it's not readily available and
only approved for administered through injection. We are working
with NIDA to create an intranasal delivery system that can make
naloxone much easier to use and more accessible for first
responders, paramedics and families and friends of addicts who are
at risk of overdose."
About Lightlake Therapeutics
Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is
using its expertise in opioid antagonists to build a platform of
innovative solutions to common addictions and related disorders.
The Company holds patents covering the use of intranasal naloxone
to treat Binge Eating Disorder ("BED") as well as patents covering
addiction to drugs including cocaine, amphetamine, and MDMA.
Lightlake is currently focused on advancing its treatment for BED,
which has successfully completed Phase II clinical trials, and a
Phase II trial is planned for the indication of Bulimia Nervosa.
Lightlake is also applying its technology to develop a treatment
for managing the complications of opioid drug addiction in
collaboration with the National Institute on Drug Abuse (NIDA),
part of the National Institutes of Health. For more information
please visit: http://www.lightlaketherapeutics.com
Forward Looking Statement
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable
law.
Media Contacts:
KCSA Strategic Communications
Anne Donohoe / Taylor McGann
+1 212.896.1261 / +1 212.896.1253
adonohoe@kcsa.com / tmcgann@kcsa.com
Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239
pcarlson@kcsa.com / jdver@kcsa.com
SOURCE Lightlake Therapeutics Inc.